secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001297184-24-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q4 net revenue $178.1M, GAAP EPS $0.68; FY revenue $644.4M
--------------------------------------------------------------------

- Q4 2023 net revenue $178.1M (+32% YoY); GAAP net income $36.2M ($0.68 EPS).
- Adjusted non-GAAP Q4 net income $46.9M ($0.88 EPS) vs $37.6M ($0.73 EPS) in Q4 2022.
- Full-year net revenue $644.4M (+29% YoY); GAAP net income $137.5M ($2.60 EPS).
- Full-year adjusted non-GAAP net income $175.7M ($3.32 EPS) vs $103.2M ($1.97 EPS) in FY2022.
- CEO cited strong performance of glucagon, Primatene MIST, BAQSIMI acquisition, and BLA submission for Insulin Aspart.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000004/0001297184-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000004/amph-20240228x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer